Haemonetics Strengthens Leadership with Strategic Appointments Haemonetics Corporation has announced key changes to its executive team. Frank Chan will join as Chief Operating Officer, overseeing R&D and global operations starting April 7, 2025. Meanwhile, Roy Galvin, now Chief Commercial Officer, will lead commercialization efforts across hospital and plasma businesses. These updates aim to propel the company’s growth strategy.1